Alkermes (ALKS) Capital Expenditures Growth (3y) (2013 - 2026)
Alkermes (ALKS) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -15.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.83% |
| Dec 31, 2025 | -26.03% |
| Sep 30, 2025 | 18.24% |
| Jun 30, 2025 | 9.32% |
| Mar 31, 2025 | 9.07% |
| Dec 31, 2024 | 4.11% |
| Sep 30, 2024 | 19.72% |
| Jun 30, 2024 | 2.72% |
| Mar 31, 2024 | 1.46% |
| Dec 31, 2023 | 46.30% |
| Sep 30, 2023 | 31.14% |
| Jun 30, 2023 | -2.82% |
| Mar 31, 2023 | -29.76% |
| Dec 31, 2022 | -32.06% |
| Sep 30, 2022 | -18.61% |
| Jun 30, 2022 | -14.44% |
| Mar 31, 2022 | -30.92% |
| Dec 31, 2021 | -21.04% |
| Sep 30, 2021 | -33.57% |
| Jun 30, 2021 | -27.10% |